Table 7 Allele and genotype distribution of patients with response and not achieving seizure free to predominant sodium channel blocking antiseizure medications

SCN1A

rs121918808

C/T

57

1

0

24

0

0

1.0000

115:1; 48:0

1.0000

rs200176684

C/T

57

0

1

24

0

0

1.0000

114:2; 48:0

0.5834

rs201985242

G/C

58

0

0

24

0

0

1.0000

116:0; 48:0

1.0000

SCN1B

rs55742440

T/C

40

17

1

12

8

4

0.0310

97:19; 32:16

0.392 (0.180–0.851)

0.0159

rs3746255

C/T

57

1

0

22

2

0

0.2036

115:1; 46:2

0.2 (0.017–2.260)

0.2052

rs67486287

G/C

41

16

1

17

5

2

0.3292

98:18; 39:9

0.796 (0.330–1.923)

0.6101

rs67701503

C/A

41

16

1

17

5

2

0.3292

98:18; 39:9

0.796 (0.330–1.923)

0.6101

rs2305748

C/T

41

16

1

17

5

2

0.3292

98:18; 39:9

0.796 (0.330–1.923)

0.6101

rs369032304

G/A

58

0

0

24

0

0

1.0000

116:0; 48:0

1.0000

rs72558026

G/A

57

1

0

20

4

0

0.0241

115:1; 44:4

0.096 (0.010–0.880)

0.0261

SCN2A

rs2060198

T/A

54

4

0

24

0

0

0.3158

112:4; 48:0

0.3222

rs17183814

G/A

41

14

3

14

9

1

0.4452

96:20; 37:11

0.701 (0.306–1.603)

0.5110

rs138497939

A/C

57

1

0

24

0

0

1.0000

115:1; 48:0

1.0000

rs185590667

T/C

57

1

0

24

0

0

1.0000

115:1; 48:0

1.0000

rs199925238

G/A

54

4

0

21

3

0

0.4418

112:4; 45:3

0.536 (0.115–2.490)

0.6746

rs186154973

G/A

57

1

0

24

0

0

1.0000

115:1; 48:0

1.0000

SCN9A

rs9646771

T/C

39

12

7

14

5

5

0.5625

90:26; 33:15

0.636 (0.300–1.346)

0.2351

rs3750904

T/C

44

11

3

18

6

0

0.6353

99:17; 42:6

1.202 (0.433–3.261)

0.7184

rs199756028

G/A

57

1

0

24

0

0

1.0000

115:1; 48:0

1.0000

rs200613417

A/T

58

0

0

23

1

0

0.2926

116:0; 47:1

0.2927

rs200956485

G/A

57

1

0

24

0

0

1.0000

115:1; 48:0

1.0000